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Neonatal ventilatory techniques – which are best for
infants born at term?
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Abstract
Few studies have examined ventilatory modes exclusively in infants born at
term. Synchronous intermittent mandatory ventilation (SIMV) compared to
intermittent mandatory ventilation (IMV) is associated with a shorter duration
of ventilation. The limited data on pressure support, volume targeted ventilation
and neurally adjusted ventilatory assist demonstrate only short term benefits
in term born infants. Favourable results of high-frequency oscillatory ventilation
(HFOV) in infants with severe respiratory failure were not confirmed in the two
randomised trials. Nitric oxide (NO) in term born infants, except in those with
congenital diaphragmatic hernia (CDH), reduces the combined outcome of death
and requirement for extracorporeal membrane oxygenation (ECMO). In infants
with severe refractory hypoxaemic respiratory failure, ECMO, except in infants
with CDH, reduced mortality and the combined outcome of death and severe
disability at long-term follow-up. Randomised studies with long term outcomes
are required to determine the optimum modes of ventilation in term born infants. 
Key words: extracorporeal membrane oxygenation, high frequency oscillation,
patient triggered ventilation, nitric oxide.
Introduction
Term-born infants require assisted ventilation for a variety of reasons,
the most common being meconium aspiration syndrome (MAS), respiratory
distress syndrome (RDS) and transient tachypnoea of the newborn (TTN) [1].
In a study of 65,000 term infants, the incidences of mechanical ventilation
for MAS, RDS and TTN were 0.61, 0.38 and 0.72 per thousand live births
respectively [1]. In a study of ventilated infants of at least 34 weeks of
gestation, pneumonia/sepsis and persistent pulmonary hypertension of
the newborn (PPHN) were also common diagnoses, approximately one
third of the infants were ventilated for non pulmonary causes (Table I) [2].
It has been estimated that 3.6 per 1000 infants born at term require
mechanical ventilation [1]. 
The mortality rate amongst term born infants requiring assisted
ventilation is high, ranging from 9.1% to 11.7% [3, 4]. Although major
congenital anomalies are a contributing factor, there is a high mortality
rate (9.6% to 12.2%) in ventilated, term born infants without major
congenital anomalies [5]. Term born infants requiring mechanical
ventilation also suffer considerable morbidity. In one study [2], 11%
developed chronic lung disease (defined as a requirement for supplemental
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Review paperoxygen at 30 days after birth) and 9% developed
neurological complications (defined as the
development of prolonged seizures despite treat  -
ment, an abnormal electroencephalogram or
abnormal brain imaging showing brain atrophy,
intracranial haemorrhage or stroke). 
There have been many studies attempting to
optimise mechanical ventilation, but these have
generally focused on prematurely born infants [6].
Prematurely born infants usually require ventilatory
support because they have lung immaturity and/or
inadequate respiratory control. In contrast, term
born infants may have vigorous respiratory drive
and can suffer from a variety of pathologies. Thus,
it cannot be assumed that ventilation modes for
prematurely born infants will be optimal for those
born at term. We, therefore, have reviewed the
literature (Table II) to determine if there are
sufficient data to make evidence based recom  -
mendations regarding optimum ventilation for
infants born at term. 
Time-cycled pressure-limited ventilation 
During intermittent mandatory ventilation (IMV)
or intermittent positive pressure ventilation (IPPV)
mechanical inflations are delivered at a pre-defined
rate regardless of the infant’s spontaneous
respiratory activity. This can lead to asynchrony,
resulting in pneumothorax [7]. In randomised trials
[8, 9], use of “fast” ventilator rates (at least 60 bpm)
was associated with a lower rate of pneumo  -
thoraces, but only in the prematurely born infants.
In one study [8], ventilation at a rate of 60 breaths
per minute (bpm) with a inspiratory time of 0.5 s
was compared to a rate of 20-40 bpm with a 1 s
inspiratory time. The number of term born infants
Pulmonary Respiratory distress syndrome 43%
Meconium aspiration syndrome 9.7%
Congenital pneumonia/sepsis 8.3%
Transient tachypnoea of the newborn 3.9%
Persistent pulmonary hypertension  3.2%
of the newborn
Aspiration of blood/amniotic fluid 2.3%
Pulmonary hypoplasia 1.4%
Non- Major congenital anomaly  21%
pulmonary eg. gastroschisis
Hypoxic-ischaemic encephalopathy 3.1%
Peri-operative support 2.1%
Undefined 5.7%
Table I. Diagnoses of term and near-term neonates
requiring mechanical ventilation [from 2]. The
percentage of infants with a particular diagnosis are
demonstrated
Reference Numbers included InterventionD esign
[8] 102 Rapid rate, short inflation time vs. slow rate,  Alternate allocation 
long inflation time to each arm
[9] 346 High frequency positive pressure ventilation  Multicentre randomised 
vs. low frequency positive pressure  controlled trial (RCT)
ventilation
[10] 327 (included 93 > 2 kg) SIMV vs. IMV Multicentre RCT
[11] 77 (included 15 term) SIMV vs. IMV RCT
[12] 20 SIMV + PS vs. SIMV RCT
[13] 9 No PSV vs. PSV 5 cm H2O vs. PSV (10 cm H2O) Randomised crossover
[14] 14 PSV + VG vs. SIMV Randomised crossover
[17] 16 PSV vs. NAVA Crossover
[26] 34 HFJV Case series
[27] 176 HFJV Case series
[28] 10 HFJV Case series
[29] 37 HFJV vs. conventional Retrospective case-control
[31] 24 HFJV vs. conventional high frequency positive  RCT
pressure ventilation
[32] 41 HFOV Case series
[33] 50 HFOV Case series
[34] 79 HFOV vs. pressure-limited time-cycled ventilation Multicentre RCT
[35] 118 HFOV vs. conventional ventilation Multicentre RCT
Table II. Studies of neonatal ventilation in term babies
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included in the study was not stated but the
pneumothoraces all occurred in infants of birth
weight less than 1.7 kg [8]. In another study
(OCTAVE) [9], rates of 60 bpm were compared to
rates of 20-40 bpm in 346 ventilated infants
without meconium aspiration. The infants suffered
from a variety of diagnoses including RDS, TTN,
pneumonia, PPHN and birth asphyxia; again, the
number of term born infants was not stated. No
significant difference in the pneumothorax rate was
demonstrated overall, but in the infants born at less
than 33 weeks of gestation it was significantly
lower at 60 compared to 20-40 bpm [9]. The results
of those studies [8, 9] suggest using ventilator rates
of 60 bpm rather than 20-40 bpm is not
advantageous in term infants with regard to
reducing pneumothoraces and there are no other
reported benefits.
Patient-triggered ventilation
During patient-triggered ventilation (PTV), the
infant’s respiratory efforts trigger mechanical
inflations. During synchronised intermittent
mandatory ventilation (SIMV) a pre-defined number
of mechanical inflations are delivered, but during
assist control ventilation (ACV) all the patient’s
respiratory efforts that exceed the critical trigger
level are supported by mechanical inflations. Infants
born at term have been included in two studies
comparing SIMV and IMV [10, 11], they show only
limited benefit of SIMV. A multicentre randomised
trial [10] included 93 infants with a birth weight
greater than 2 kg and a mean gestational age of 36
weeks; the study was adequately powered for
subgroup analysis with respect to oxygenation
index and the incidence of air leaks. Infants of birth
weight greater than 2 kg supported by SIMV had
a shorter duration of ventilation (p = 0.02), but had
similar rates of death, air leak and oxygen
dependency at 28 days. In the other randomised
trial [11], there were no significant differences in the
duration of ventilation, need for reintubation or
pneumothorax or mortality rates between infants
supported by SIMV or IMV, only 15 infants born at
term (all with MAS) were included. 
Pressure support ventilation
During pressure support ventilation (PSV),
ventilator inflation is not only initiated by the baby’s
inspiratory effort, but is terminated when the
infant’s inspiratory flow declines to a predefined
level. The level may be fixed (eg. 15% of inspiratory
flow with the Dräger Babylog 8000 plus) or can be
varied by the clinician between 5% and 25% (VIP
Bird and SLE 5000 ventilators). The data regarding
the efficacy of PSV are limited, certain results
suggest use of PSV might be advantageous in
infants born at or near term [12, 13], but this is not
a consistent finding [14]. In a study of 20 infants,
including five infants born at term, addition of
pressure support to SIMV compared to SIMV alone
was associated with a reduction in the work of
breathing (p < 0.001); no sub-analysis, however,
was done with respect to maturity at birth [12]. In
nine term-born infants with congenital heart
disease, studied post-operatively or post-cardiac
catheterisation, increasing levels of pressure
support added to continuous positive airway
pressure (CPAP) was associated with increased tidal
volumes, minute ventilation and inspiratory flow
[13]. In contrast, in a crossover trial [14] of 4 h
periods of PSV plus volume guarantee (VG) or SIMV
including 14 infants with a mean gestational age of
34 weeks and birth weight of 2.5 kg recovering from
RDS, although, minute ventilation and mean airway
pressure were significantly higher and functional
residual capacity significantly lower during PSV plus
VG, there were no significant differences in the
carbon dioxide levels, arterial/alveolar oxygen
tension or dynamic compliance results according
to ventilator mode. The authors concluded that PSV
with VG could not be recommended [14], but others
[15] have questioned the study design and data
collection, including measuring dynamic compliance
without assessing oesophageal pressure and hence
the infant’s contribution to the trans-pulmonary
pressure changes.
Proportional assist ventilation
Proportional assist ventilation (PAV) is a more
sophisticated form of PTV, during which the infant’s
spontaneous respiratory effort determines the
frequency, timing and rate of lung inflation. The
clinician can set levels of elastic and resistive
unloading to reduce the infant’s work of breathing.
Clinical studies of PAV in infants have only included
those born prematurely. An in vitro study, however,
has been carried out using lung models which
mimicked the lung function abnormalities, not only
of infants with RDS and BPD, but also those with MAS
[16]. It demonstrated that pressures delivered by the
ventilator were between 1 cm to 4 cm H2O in excess
of those expected and oscillations appeared in the
airway pressure wave form as the unloading was
increased, the level being dependent on the lung
function abnormalities of the lung model. There was
also a delay in the delivery of airway pressure of at
least 60 ms [16]. Unloading did reduce the inspiratory
load, but it was concluded that the possible impact
of the waveform abnormalities and time lag in the
inflation pressure delivery needed careful evaluation
in the clinical setting [16]. 
Neurally adjusted ventilatory assist
Neurally adjusted ventilatory assist (NAVA) uses
diaphragmatic electrical activity (EAdi) to trigger384 Arch Med Sci 3, June / 2011
and cycle off ventilator support. The EAdi signals
are detected by electrodes which are mounted on
a nasogastric tube which is positioned such that
the electrode array spans the diaphragm. The
clinician can set the level of ventilator assist as
‘NAVA gain’, which determines the magnitude of
ventilator pressure delivered in relation to the EAdi.
There are limited data on the use of NAVA in
infants, but that available highlight short term
benefits. NAVA was compared to PSV in a crossover
designed study in infants and children, including
seven infants born at term, six with congenital
heart disease and one with a congenital dia  -
phragmatic hernia [17]. Neurally adjusted ven  -
tilatory assist was associated with significantly
better synchrony and lower peak airway pressures
at 30 min and 3 h [17]. In another crossover study
[18], NAVA was compared to PSV in 21 infants with
a mean age of 2.9 ±2.1 months studied after cardiac
surgery. Three could not be ventilated with NAVA
due to diaphragmatic paralysis but, in the remaining
18 infants, the peak inflating pressures and EAdi
were significantly lower during NAVA without
differences in the carbon dioxide clearance. 
Volume-targeted ventilation
During volume-targeted ventilation (VTV), a pre  -
determined volume is delivered despite changes in
the infant’s respiratory function. This is achieved
by servo-controlled adjustments in the inflating
pressure in response to differences in either the
exhaled or inhaled volume. There are different
forms of VTV: volume guarantee (VG), volume
controlled, volume limited, pressure-regulated
volume control (PRVC) and volume-assured
pressure support (VAPS). Ventilator manufacturers
have used different strategies to achieve VTV and
this results in differences in the airway pressure
wave form [19]. Volume-targeted ventilation can be
used in conjunction with other modes such as IPPV,
SIMV, ACV or PSV. In adults use of a higher 
(12 ml/kg) rather than a lower (6 ml/kg) tidal
volume was associated with a significantly higher
mortality rate [20] and larger volumes are also more
likely to cause endothelial and peripheral airway
injury [21]. In a randomised trial (n = 22), infants
aged 1 to 9 months with congenital heart disease
studied post-operatively who were ventilated with
VT levels of 10-12 ml/kg rather than 6-8 ml/kg had
significantly higher serum levels of the pro-
inflammatory cytokine interleukin-6, as well as
a trend to worsening oxygenation [22]. Evidence
from prematurely born infants, however, highlights
that too a low tidal volume should also be avoided
[23, 24]. Increased levels of inflammatory markers
in tracheal aspirates were found when a volume
target level of 3ml/kg rather than 5ml/kg was used
[23] and in another study [24], there was an
increased work of breathing at 4ml/kg compared
to levels of 5 and 6ml/kg [24]. The optimum VT level
in term born infants and whether this varies
according to the type of respiratory pathology
needs to be determined. 
High frequency jet ventilation
During high frequency jet ventilation (HFJV), brief
pulses of gas at high pressure are delivered through
a small-bore injector cannula in a triple-lumen
endotracheal tube or via an adapter attached to the
proximal end of an endotracheal tube. A constant
background of positive end expiratory pressure
(PEEP) is provided by a conventional ventilator
operating in tandem. Rates of 200-600 per minute
are used and the high velocity pulses of gas entrain
humidified gas down the endotracheal tube. Non
controlled studies reported results of HFJV in both
term and preterm infants. In the earlier studies [25,
26], use of HFJV was associated with a significant
improvement in both oxygenation and carbon
dioxide tensions, but fatal necrotising tracheo  -
bronchitis was a major complication. In addition, in
one study [26] fatal pneumopericardia occurred in
3 out of 23 patients with air leaks. A subsequent
study [27] also highlighted significant impro  -
vements in PaO2 and PaCO2 at lower FiO2, PIP and
MAP levels on HFJV, but only a 4% rate of
necrotising tracheobronchitis and a 3% rate of
pneumopericardium. Friedlich et al. [28] also
reported HFJV resulted in significant reductions in
the oxygenation index, FiO2 and MAP levels in
neonates with hypoxaemia refractory to HFOV.
A retrospective comparison of 14 term neonates
with PPHN treated with HFJV with 23 similar infants
treated with conventional ventilation demonstrated
that the infants supported by HFJV had significantly
lower oxygen indices (OI), PaCO2 and MAP levels
[29]. There were, however, no significant differences
between the two groups in their alveolar-arterial
oxygen gradients, incidence of air leaks or
bronchopulmonary dysplasia (BPD) or their dura  -
tions of ventilation or supplementary oxygen
dependencies [29]. A retrospective evaluation of
the role of HFJV prior to ECMO in 73 term neonates
reported those with severe meconium aspiration or
congenital diaphragmatic hernia were less likely to
respond to HFJV compared to infants with other
causes of respiratory failure [30]. There has been
only one randomised controlled trial comparing
HFJV to high frequency positive pressure ventilation
(HFPPV) in term and near-term infants, it included
24 infants with respiratory failure and PPHN [31].
The HFJV group experienced a significant acute rise
in PaO2 and a decrease in PaCO2 and OI, whereas
the HFPPV group required a significant increase in
their peak inflating pressures to maintain gas
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exchange. There were no significant differences in
the rates of survival without ECMO, air leak or
chronic lung disease or the duration of ventilation.
One of 11 babies in HFJV arm developed tracheitis
and one of 13 babies in the conventional arm
tracheal obstruction [31]. 
High-frequency oscillatory ventilation
During high-frequency oscillatory ventilation
(HFOV), small tidal volumes are delivered at fast
rates, that is, greater than 5 Hz. Two uncontrolled
“rescue” studies showed a beneficial effect of HFOV
in term born neonates with severe respiratory
failure [32, 33]. In 41 infants with pulmonary
hypertension due to a variety of conditions
including TTN, pneumonia, MAS, RDS and Group B
Streptococcal sepsis, three infants died and in four
infants HFOV could not be successfully established
[32]. In the remaining 34 infants, however, there
was a significant rise in the mean arterial/alveolar
oxygen tension ratio and reductions in the arterial
carbon dioxide tension and mean airway pressure
within 12 h of initiating HFOV [32]. In another 
series [33], 21 of 50 infants admitted for
extracorporeal membrane oxygenation (ECMO)
responded to HFOV. There were no significant
differences between the infants who were rescued
by HFOV and those who required ECMO with regard
to their durations of ventilation or hospital stay or
survival rates [33]. The results, however, from two
multi-centre randomised controlled trials [34, 35],
which have compared HFOV to conventional
ventilation in term and near-term infants with
severe respiratory failure, did not highlight benefits.
One study [34] included infants of more than 34
weeks of gestational age and more than 2 kg in
birth weight. The infants’ diagnoses included
pneumonia, RDS, MAS, pulmonary hypoplasia and
air leak. No differences were detected in the rates
of treatment failure, need for ECMO, chronic lung
disease or survival or the duration of ventilation,
but 63% of the 24 infants, assigned to conventional
ventilation and meeting treatment failure criteria,
responded to HFOV. The trial, however, was
prematurely terminated (n = 79, sample size
calculation 250) due to difficulty in recruitment. In
the second study [35], which included newborns of
more than 35 weeks of gestation and birth weight
greater than 1.75 kg, there were no significant
differences in either the primary (death and
pulmonary air leak) or secondary (chronic lung
disease, duration of ventilation and treatment
failure) outcomes. The planned sample size was 200
babies, but the study was terminated when 118
infants had been recruited as the interim analysis
did not demonstrate any statistically significant
difference in the primary outcome. The Cochrane
review [36] of HFOV vs. conventional ventilation in
term or near-term infants with severe respiratory
failure analysed data from those two studies [34,
35] and concluded that there was no evidence to
support the use of HFOV in term and near-term
infant with severe respiratory failure. 
Nitric oxide
Inhaled NO (iNO) is a selective pulmonary
vasodilator and is used in severe hypoxaemic
respiratory failure associated with pulmonary
hypertension. The Cochrane review [37] of iNO for
respiratory failure in term and near-term infants
includes 14 studies. Meta-analysis of the results of
those 14 trials highlighted that use of iNO was
associated with a significant reduction in the
combined outcome of death or requirement for
ECMO (relative rate (RR) 0.68, 95% confidence
intervals (CI) 0.59-0.79). There was no significant
difference in the mortality rate (RR 0.91, 95% CI 0.6-
1.37), but a significant reduction in the requirement
for ECMO (RR 0.63, 95% CI 0.54-0.75). In a subgroup
of 84 infants with CDH, there were no significant
differences in the combined outcome of death or
requirement for ECMO (RR 1.09, 95% CI 0.95-1.26)
or mortality rate (RR 1.2, 95% CI 0.74-1.96) and
a marginally significant increase in the requirement
for ECMO (RR 1.27, 95% CI 1.00-1.62).
Extracorporeal membrane oxygenation
Extracorporeal membrane oxygenation (ECMO)
is a form of cardiopulmonary bypass. In veno-
arterial (VA) ECMO, blood is drained from the right
atrium via the right internal jugular vein and
returned to the aorta via the right carotid artery,
total cardiopulmonary bypass is achieved. In veno-
Suitability Gestational age ≥ 34 weeks
Birth weight ≥ 2000 g
Reversible pulmonary disease 
Duration of mechanical ventilation 
< 10-14 days
No significant coagulopathy  
or active bleeding
No major intracranial haemorrhage
No lethal congenital malformation
No uncorrectable congenital heart disease
No evidence of irreversible brain damage
Respiratory Oxygenation index (OI) 35-60 for 0.5-6 h
status
PaO2 < 35 to < 60 mmHg for 2-12 h
[39, 40]
Arterial pH < 7.25 for 2 h or with hypotension
Acute deterioration of PaO2 to < 30 
to < 40 mmHg
Table III. Neonatal ECMO386 Arch Med Sci 3, June / 2011
venous (VV) ECMO, blood is drained from and
returned to the right atrium via a double-lumen
catheter. The advantage of VA ECMO is that
approximately 80% cardiopulmonary bypass is
achieved and thus the level of respiratory support
can be reduced. During VV ECMO, carotid artery
cannulation is avoided, but the infant must have
good myocardial function. Indications for ECMO
have included an oxygenation index of more than 40
on two or more arterial blood gases [38] (Table III).
The UK collaborative study [39] is the largest
randomised study evaluating ECMO in neonates
and demonstrated ECMO was associated with
a 45% reduction in mortality in infants of greater
that 34 weeks of gestation with severe respiratory
failure. The Cochrane review [40] of ECMO for
severe respiratory failure in newborns assessed four
trials, including the UK collaborative study. Meta-
analysis of the results of those four trials indicated
that ECMO significantly reduced death (RR 0.51,
95% CI 0.37 to 0.7), especially for babies without
CDH (RR 0.41, 95% CI 0.27 to 0.63). Long term
follow-up of the UK collaborative study has
demonstrated a reduction in the combined
outcome of death or severe disability at 1 (RR 0.56,
95% CI 0.40 to 0.78) [39], at 4 [41] and 7 years [42]
(RR 0.62, 95% CI 0.45 to 0.86).
Liquid ventilation 
Liquid ventilation is achieved by instillation of
perfluorocarbons (PFC) into the lungs. Perfluoro  -
carbons are inert compounds with low surface
tension and high solubility for oxygen and carbon
dioxide. Total liquid ventilation involves completely
filling the lungs and ventilator circuit with PFC,
whereas partial liquid ventilation (PLV) involves
filling the lungs with PFC to approximately the
functional residual capacity and then applying “on
top” conventional ventilation. Data from in vitro
studies suggest there could be numerous
advantages to using liquid ventilation [43], but
clinical data including term born infants are limited.
Hirschl et al. [44] included five term born infants
(four with CDH and one with PPHN) in a study of
PLV in adults, children and infants with severe
respiratory failure on ECMO [40]. Significant
improvements in the alveolar-arterial oxygen
difference and static pulmonary compliance were
noted on commencement of PLV. Use of PLV was
associated with few adverse events, but there was
re-accumulation of pneumothoraces in 6 patients,
development of new pneumothoraces in three and
patients and there was extravasation of PFC into
the pleural space in 3 patients with pneumo  -
thoraces. Further studies are required to determine
if liquid ventilation offers advantages over other
respiratory support techniques in term born
neonates.
Recommendations
• Infants should be started on time cycled, pressure
limited ventilation at rates of 30 to 40 bpm.
• Infants with evidence of pulmonary hypertension
should receive inhaled nitric oxide.
• Infants with severe respiratory failure should be
referred for consideration of ECMO except infants
with congenital diaphragmatic hernia who should
be considered on a case by case basis. 
Research directions
• All new modes of ventilatory support for use in
term born infants should be optimised using in
vivo models and then studies with physiological
outcomes, in particular determining if optimal
modes very with the underlying diagnosis.
• Subsequently, appropriately designed studies with
long term outcomes need to be undertaken.
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